Lydia Foster1, Laura Robinson2, Sharon D Yeatts1, Robin A Conwit3, Amjad Shehadah2, Vasileios Lioutas2, Magdy Selim2. 1. Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.F., S.D.Y.). 2. Stroke Division, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (L.R., A.S., V.L., M.S.). 3. National Institute of Neurological Disorders and Stroke, Bethesda, MD (R.A.C.).
Abstract
BACKGROUND: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke. The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period. We evaluated the trajectory of mRS among trial participants and examined the effect of deferoxamine on this trajectory. METHODS: We performed a post hoc analysis of the i-DEF trial, a multicenter, randomized, placebo-controlled, double-blind, futility-design, phase 2 clinical trial, based on the actual treatment received. Favorable outcome was defined as mRS score of 0-2. A generalized linear mixed model was used to evaluate the outcome trajectory over time, as well as whether the trajectory was altered by deferoxamine, after adjustments for randomization variables, presence of intraventricular hemorrhage, and ICH location. RESULTS: A total of 291 subjects were included in analysis (145 placebo and 146 deferoxamine). The proportion of patients with mRS score of 0-2 continually increased from day 7 to 180 in both groups (interaction P<0.0001 for time in main effects model), but treatment with deferoxamine favorably altered the trajectory (interaction P=0.0010). Between day 90 and 180, the deferoxamine group improved (P=0.0001), whereas there was not significant improvement in the placebo arm (P=0.3005). CONCLUSIONS: A large proportion of patients continue to improve up to 6 months after ICH. Future ICH trials should assess outcomes past 90 days for a minimum of 6 months. In i-DEF, treatment with deferoxamine seemed to accelerate and alter the trajectory of recovery as assessed by mRS. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02175225.
BACKGROUND: There are limited data on the trajectory of recovery and long-term functional outcomes after intracerebral hemorrhage (ICH). Most ICH trials have conventionally assessed outcomes at 3 months following the footsteps of ischemic stroke. The i-DEF trial (Intracerebral Hemorrhage Deferoxamine Trial) assessed modified Rankin Scale (mRS) longitudinally at prespecified time points from day 7 through the end of the 6-month follow-up period. We evaluated the trajectory of mRS among trial participants and examined the effect of deferoxamine on this trajectory. METHODS: We performed a post hoc analysis of the i-DEF trial, a multicenter, randomized, placebo-controlled, double-blind, futility-design, phase 2 clinical trial, based on the actual treatment received. Favorable outcome was defined as mRS score of 0-2. A generalized linear mixed model was used to evaluate the outcome trajectory over time, as well as whether the trajectory was altered by deferoxamine, after adjustments for randomization variables, presence of intraventricular hemorrhage, and ICH location. RESULTS: A total of 291 subjects were included in analysis (145 placebo and 146 deferoxamine). The proportion of patients with mRS score of 0-2 continually increased from day 7 to 180 in both groups (interaction P<0.0001 for time in main effects model), but treatment with deferoxamine favorably altered the trajectory (interaction P=0.0010). Between day 90 and 180, the deferoxamine group improved (P=0.0001), whereas there was not significant improvement in the placebo arm (P=0.3005). CONCLUSIONS: A large proportion of patients continue to improve up to 6 months after ICH. Future ICH trials should assess outcomes past 90 days for a minimum of 6 months. In i-DEF, treatment with deferoxamine seemed to accelerate and alter the trajectory of recovery as assessed by mRS. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02175225.
Authors: David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman Journal: BMJ Date: 2010-03-23
Authors: Magdy Selim; Lydia D Foster; Claudia S Moy; Guohua Xi; Michael D Hill; Lewis B Morgenstern; Steven M Greenberg; Michael L James; Vineeta Singh; Wayne M Clark; Casey Norton; Yuko Y Palesch; Sharon D Yeatts Journal: Lancet Neurol Date: 2019-03-18 Impact factor: 44.182
Authors: Anirudh Sreekrishnan; Audrey C Leasure; Fu-Dong Shi; David Y Hwang; Joseph L Schindler; Nils H Petersen; Emily J Gilmore; Hooman Kamel; Lauren H Sansing; David M Greer; Kevin N Sheth Journal: Neurocrit Care Date: 2017-12 Impact factor: 3.210
Authors: Masanobu Okauchi; Ya Hua; Richard F Keep; Lewis B Morgenstern; Timothy Schallert; Guohua Xi Journal: Stroke Date: 2009-12-31 Impact factor: 7.914
Authors: Daniel F Hanley; Richard E Thompson; John Muschelli; Michael Rosenblum; Nichol McBee; Karen Lane; Amanda J Bistran-Hall; Steven W Mayo; Penelope Keyl; Dheeraj Gandhi; Tim C Morgan; Natalie Ullman; W Andrew Mould; J Ricardo Carhuapoma; Carlos Kase; Wendy Ziai; Carol B Thompson; Gayane Yenokyan; Emily Huang; William C Broaddus; R Scott Graham; E Francois Aldrich; Robert Dodd; Cristanne Wijman; Jean-Louis Caron; Judy Huang; Paul Camarata; A David Mendelow; Barbara Gregson; Scott Janis; Paul Vespa; Neil Martin; Issam Awad; Mario Zuccarello Journal: Lancet Neurol Date: 2016-10-11 Impact factor: 44.182